Site comparison
Amavita Research vs. Altior Clinical Research: which clinical trial site fits your study?
Sponsors evaluating South Florida sites sometimes compare a dedicated cardiovascular specialist against a smaller, growing multi-therapeutic site. The two models target different sponsor needs.
Altior Clinical Research is a South Florida site running Phase I-IV studies across multiple therapeutic areas. As a smaller, growing multi-therapeutic site, the typical positioning is breadth across indications and willingness to support a wide phase range. For sponsors with mixed-indication portfolios who want a single contractual relationship at one site, that flexibility is useful.
Amavita Research is a dedicated cardiovascular research site led by U.S. TAVR pioneer Dr. William W. O'Neill, who has served as National PI on Edwards PARTNER, Protect II, and Protect IV. Every active protocol is cardiovascular, and the affiliated Advanced Cardiovascular of Miami ASC supports interventional procedures on site.
The trade-off is leadership depth and operational concentration. A multi-therapeutic site distributes PI bandwidth, coordinator training, and regulatory specialization across several disease areas. A cardiovascular-only site concentrates all of it on heart failure, structural heart, hypertension, ACS, and PAD - the indications a sponsor running a cardiovascular protocol actually cares about.
Amavita's GCSA-certified processes, ICH-GCP E6(R3) compliance, single BD contact (Nereisy Alonso, Sr CRC), and TAVR-pioneer PI leadership are not features that scale automatically with site size. They reflect a deliberate choice to stay narrow and deep.
For sponsors with multi-therapeutic portfolios looking for a flexible South Florida partner, Altior fits. For sponsors who want the deepest cardiovascular bench in Miami with single-PI accountability, Amavita fits.
Side-by-side: operating model
Educational summary. We describe the typical multi-therapeutic research site model and do not make claims about any specific institution's current operations.
| Dimension | Amavita Research | Altior (typical) |
|---|---|---|
| Site type | Dedicated cardiovascular research site | Multi-therapeutic research site |
| Cardiovascular focus depth | 100% cardiovascular - all studies, all PIs | One of multiple therapeutic areas |
| Senior PI profile | TAVR pioneer; National PI on Edwards PARTNER, Protect II, Protect IV | Multi-therapeutic PI roster |
| Dedicated cardiovascular ASC | On-site cardiovascular ASC (Advanced Cardiovascular of Miami) | Typically external referral |
| BD contact model | Single point of contact: Nereisy Alonso, Sr CRC | Shared across therapeutic areas |
| FDA Diversity Action Plan readiness | Miami patient mix - FDA Diversity Action Plan native | South Florida catchment |
| AI-search readiness | llms.txt + Wikidata + MedicalStudy/JobPosting/FAQ schema | Standard site website |
Frequently asked questions
Why does PI leadership profile matter to a sponsor?
For pivotal cardiovascular trials, a senior PI with National PI experience on landmark trials brings protocol literacy, monitoring relationships, and credibility with regulators that meaningfully affect program outcomes.
Does Amavita support early-phase cardiovascular work?
Yes, when the protocol is cardiovascular. Amavita's bench supports first-in-human cardiovascular work with appropriate safety oversight.
Can a smaller multi-therapeutic site outperform a specialist on cost?
Cost models vary. The more meaningful question is total program cost including enrollment timeline risk, where specialist sites typically reduce delay risk on cardiovascular protocols.
When does multi-therapeutic flexibility win?
When a sponsor wants one contractual relationship covering several disease areas at one address, multi-therapeutic sites simplify administration.
Next step
Schedule a 20-minute capabilities call
One contact. Same-business-day response. Feasibility, budget, contracts, and monitor access all from a single owner.